This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Pneumococcal 15-valent polysaccharide conjugate vaccine

Updated 2 Feb 2023 | Pneumococcal vaccine


Vaccine containing polysaccharide from 15 capsular types of pneumococcus.

Drugs List

  • pneumococcal 15-valent polysaccharide conjugate vaccine pre-filled syringe
  • VAXNEUVANCE vaccine suspension for injection
  • Therapeutic Indications


    Vaccination against pneumococcal diseases

    Active immunisation against invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F.

    Vaccination should be based on official recommendations and the variability of serotype epidemiology in different geographical areas. The impact of invasive disease at different age groups should be considered.

    Individuals at an increased risk from pneumococcal infection:

    Asplenia or splenic dysfunction (including homozygous sickle cell disease and coeliac disease which could lead to splenic dysfunction).

    Chronic respiratory disease (including chronic obstructive pulmonary disease, chronic bronchitis, emphysema, bronchiectasis, cystic fibrosis, interstitial lung fibrosis, pneumoconiosis and bronchopulmonary dysplasia, children with respiratory conditions caused by aspiration, or neurological disease (e.g. cerebral palsy) with risk of aspiration, asthma that requires the use of oral steroids at a dose sufficient to act as a significant immunosuppressant).

    Chronic heart disease (including those requiring medication/follow up for ischaemic heart disease, congenital heart disease, hypertension with cardiac complications, and chronic heart failure).

    Chronic renal disease (including nephrotic syndrome, chronic renal failure, and renal transplantation).

    Chronic hepatic disease (including cirrhosis, biliary atresia, and chronic hepatitis).

    Diabetes (requiring insulin or oral hypoglycaemic drugs).

    Immunosuppression (due to disease or treatment. Including asplenia or splenic dysfunction, HIV infection at all stages, patients undergoing immunosuppressive chemotherapy. Individuals on or likely to be on systemic steroids for more than one month at a dose equivalent to prednisolone at 20mg or more per day (any age), or for children under 20kg, a dose of 1mg or more per kg per day).

    Individuals with cochlear implants (immunisation should not delay cochlear implantation).

    Individuals with cerebrospinal fluid leaks (includes leakage following trauma or major skull surgery).

    Children under 5 years with a history of invasive pneumococcal disease.

    Individuals at occupational risk.

    For comprehensive information or advice on this product or the immunisation programme in the UK, the following website should be accessed.



    1 Dose (0.5mL).


    The vaccine should be given by intramuscular injection preferably in the deltoid muscle.


    Acute infection
    Children under 18 years
    Severe febrile conditions

    Precautions and Warnings

    Immunodeficiency syndromes

    Postpone immunisation if there is active or suspected infection
    Impaired response possible in immunocompromised patients
    Prophylactic antibiotic therapy should continue after immunisation
    Vaccine may not be effective in 100% of patients
    Delay treatment if acute febrile illness
    Do not mix with other vaccines in the same syringe
    Have adrenaline injection ready for use in case of anaphylaxis
    Inject other vaccines at different sites
    Record name and batch number of administered product
    Resuscitation facilities must be immediately available
    Severe, sudden fever may require early antimicrobial use - advise patients
    Follow national immunisation guidelines

    Pregnancy and Lactation


    Use pneumococcal 15-valent polysaccharide conjugate vaccine with caution during pregnancy.

    The manufacturer states that caution should be exercised when pneumococcal 15-valent polysaccharide conjugate vaccine is administered during pregnancy when the potential benefits outweigh the potential risk to the mother and foetus.

    At the time of writing there is limited published information regarding the use of pneumococcal 15-valent polysaccharide conjugate vaccine during pregnancy. Potential risks are unknown.


    Use pneumococcal 15-valent polysaccharide conjugate vaccine with caution during breastfeeding.

    The manufacturer states that caution should be exercised when pneumococcal 15-valent polysaccharide conjugate vaccine is administered during breastfeeding and it is unknown whether the vaccine is excreted in breast milk.

    Side Effects

    Bruising at injection site
    Erythema at injection site
    Hypersensitivity reactions
    Local pain (injection site)
    Sensation of warm at injection site
    Swelling (injection site)
    Throat tightness
    Tongue oedema

    Further Information

    Last Full Review Date: October 2022

    Reference Sources

    Immunisation against infectious disease (The Green Book).
    Available at:
    Last revised: 15 June 2022
    Last accessed: 11 October 2022

    Summary of Product Characteristics: Vaxneuvance. Merck Sharp and Dohme (UK) Limited. Revised June 2022.

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.